SIGLEC15 is a transmembrane protein that has recently garnered attention for its immunosuppressive capabilities across diverse solid tumor types, including breast cancer. Despite its relatively nascent characterization, accumulating evidence suggests that SIGLEC15 functions as a pivotal immune checkpoint molecule, distinct from the classical PD-1/PD-L1 axis, and may orchestrate tumor immune evasion by modulating myeloid cells and T-cell activity. Given these insights, a comprehensive elucidation of SIGLEC15’s role in breast cancer biology could unveil novel avenues for therapeutic intervention and biomarker-driven treatment stratification.

A team of investigators from Chongqing Medical University undertook an integrative study employing multi-omics datasets—namely TCGA (The Cancer Genome Atlas), GTEx (Genotype-Tissue Expression), and GEO (Gene Expression Omnibus)—to dissect the clinical and molecular significance of SIGLEC15 in breast cancer. Their analyses revealed a paradoxical yet intriguing association: elevated SIGLEC15 expression correlated with improved overall survival and favorable five-year prognosis. This counterintuitive finding challenges the conventional notion of immune checkpoints merely facilitating tumor progression, suggesting a complex and context-dependent functional spectrum for SIGLEC15 within the tumor milieu.

Delving deeper through single-cell RNA sequencing (scRNA-seq) of breast cancer tissue samples, the researchers pinpointed SIGLEC15 expression predominantly in malignant epithelial cells. These SIGLEC15-positive populations were characterized by a notable reduction in infiltrating CD4⁺ and CD8⁺ T-lymphocytes along with diminished presence of M0 and M1 macrophage subsets. Conversely, there was an enrichment of dendritic cells and B cells, indicative of a shift toward humoral immune mechanisms and an immunosuppressive microenvironment less conducive to cytotoxic T-cell mediated tumor eradication. This immune landscape remodeling underscores SIGLEC15’s role in shaping cellular cross-talk within the TME to favor immune escape.

Beyond its immunomodulatory effects, SIGLEC15 emerged as a critical regulator of epithelial–mesenchymal transition (EMT), a key driver of tumor invasiveness and metastasis. Functional assays demonstrated that SIGLEC15 exerts suppressive control over EMT by downregulating ZEB1, a master transcriptional regulator of this process. Overexpression models in the aggressive breast cancer cell lines BT549 and MDA-MB-231 revealed marked decreases in ZEB1 protein levels alongside classical mesenchymal markers such as N-cadherin and vimentin. Correspondingly, these alterations translated into diminished migratory and invasive capabilities as evidenced by wound healing assays and transwell migration metrics.

Conversely, silencing SIGLEC15 in MDA-MB-231 cells elicited robust enhancement in EMT phenotypes, underpinning its tumor suppressor-like function with respect to metastatic potential. These reciprocal functional validations underscore SIGLEC15’s dualistic role, whereby it modulates both immune suppression and tumor cell plasticity — a nuanced interplay that challenges prevailing assumptions and invites reconsideration of its utility as a therapeutic target.

Importantly, their investigation extended to therapeutic vulnerability profiling, revealing that high SIGLEC15-expressing breast tumors exhibited lower sensitivity to conventional platinum-based chemotherapies and PARP inhibitors, agents typically efficacious in DNA damage response deficient malignancies. Intriguingly, these same tumors demonstrated pronounced susceptibility to Nutlin-3a, a small-molecule antagonist of MDM2 that stabilizes and activates p53 tumor suppressor pathways. This finding suggests that SIGLEC15 expression status might serve as a predictive biomarker for tailoring treatment regimens, prioritizing MDM2 inhibition in tumors less amenable to DNA-damaging agents.

In vivo xenograft studies corroborated these insights, with Nutlin-3a markedly suppressing tumor growth in SIGLEC15-overexpressing models while low-SIGLEC15 tumors were more responsive to carboplatin chemotherapy. This mechanistic synergy between SIGLEC15 expression and drug response highlights the potential for integrating molecular diagnostics into therapeutic decision-making, advancing the paradigm of personalized medicine in breast cancer care.

Collectively, this comprehensive work delineates SIGLEC15 as a multifaceted mediator within the breast cancer TME that simultaneously modulates immune architecture and tumor cell invasive behavior. Its dual capacity to suppress EMT and orchestrate an immunosuppressive microenvironment positions it uniquely at the crossroads of tumor progression and immune evasion, rendering it a compelling candidate for translational research and clinical exploitation.

The implications are profound: beyond serving as a prognostic biomarker, SIGLEC15 may guide therapeutic selection—steering patients toward MDM2 inhibitors when overexpressed, while identifying those poised to benefit from platinum-based regimens in its absence. Furthermore, targeting SIGLEC15 or its downstream pathways could potentiate novel immunotherapeutic strategies that circumvent immune checkpoint resistance and metastasis.

This study exemplifies the power of integrating genomic, transcriptomic, and functional data to unravel complex tumor biology and paves the way for future clinical trials assessing SIGLEC15-targeted approaches. As breast cancer treatment pivots toward increasingly sophisticated and individualized paradigms, deciphering the molecular underpinnings of players like SIGLEC15 will be indispensable in improving patient outcomes and quality of life.

Subject of Research: Breast cancer; tumor microenvironment; SIGLEC15; immunosuppression; epithelial–mesenchymal transition

Article Title: SIGLEC15 modulates the immunosuppressive microenvironment and suppresses malignant phenotypes in triple-negative breast cancer

Web References:
https://www.sciencedirect.com/journal/genes-and-diseases
http://dx.doi.org/10.1016/j.gendis.2025.101799

References:
ZhaoFu Tan, Hongbin Xin, Jian Chen, Ming Lei, Gang Tu, Lingfeng Tang. SIGLEC15 modulates the immunosuppressive microenvironment and suppresses malignant phenotypes in triple-negative breast cancer. Genes & Diseases. DOI: 10.1016/j.gendis.2025.101799

Image Credits: ZhaoFu Tan, Hongbin Xin, Jian Chen, Ming Lei, Gang Tu, Lingfeng Tang

Keywords: Breast cancer, SIGLEC15, tumor microenvironment, immunosuppression, epithelial–mesenchymal transition, MDM2 inhibitor, Nutlin-3a, chemoresistance, single-cell RNA sequencing, prognostic biomarker

Esophageal squamous cell carcinoma remains a formidable clinical challenge, owing to its aggressive nature and often late-stage diagnosis. Traditional prognostic markers center on TNM staging, yet these fail to fully capture the complexity of host-tumor immune interactions. The study under review aggregates data from seven distinct studies encompassing nine datasets, utilizing rigorous statistical models to parse the relationship between TLS presence, tumor staging, and survival metrics such as overall survival (OS) and progression-free survival (PFS).

Their meta-analysis compellingly demonstrates that TLS presence correlates with more advanced T stage, exhibiting an odds ratio of 2.65, indicating that tumors with TLS are over two and a half times more likely to present at a higher T stage compared to TLS-negative tumors. Interestingly, the presence of TLS did not correlate significantly with nodal involvement (N stage), rendering this immune microenvironment feature somewhat independent of lymphatic spread.

Beyond staging correlations, the prognostic implications of TLS were profound. Patients harboring TLS within their tumor tissues exhibited dramatically improved OS and PFS, with hazard ratios of 0.49 and 0.56 respectively. These statistics suggest that TLS presence halves the risk of mortality and disease progression in ESCC patients, a transformative insight that may reframe clinical risk assessment paradigms. Crucially, the robustness of these associations was accentuated when TLS detection employed combined hematoxylin and eosin (HE) staining alongside immunohistochemistry (IHC), lowering hazard ratios further to 0.40 for OS and 0.50 for PFS.

From a mechanistic perspective, the study reaffirms the hypothesis that TLS function as in situ lymphoid organs, orchestrating coordinated adaptive immune responses against tumor antigens. Comprised of distinct T-cell zones, B-cell follicles, and specialized antigen-presenting cells, TLS may foster effective tumor antigen presentation and immunological memory formation. This architectural complexity likely underpins the survival advantage seen in patients with TLS-positive ESCC, reflecting a more immunologically vigilant tumor microenvironment.

The clinical ramifications of these findings are manifold. Currently, immunotherapies such as immune checkpoint inhibitors have revolutionized treatment for various malignancies but show variable efficacy in ESCC. The identification of TLS as a biomarker could refine patient stratification, identifying individuals more likely to respond favorably to immunomodulatory treatments. Additionally, the apparent independence of TLS presence from nodal status suggests that immune microenvironment signatures could supplement or even supersede traditional pathological staging in certain contexts.

Nevertheless, this meta-analysis underscores the critical importance of standardized TLS assessment methodologies. Variations in TLS identification criteria across studies complicate direct comparisons. The enhanced prognostic power detected with combined HE and IHC techniques advocates for integrative diagnostic protocols, harnessing both morphological and molecular markers to accurately characterize TLS.

Future research avenues will need to unravel the precise molecular cues governing TLS formation and maintenance within ESCC. Understanding these pathways could unlock strategies to therapeutically induce TLS neogenesis, thereby converting “cold” tumors with poor immune infiltration into “hot” tumors amenable to immunotherapy. Intriguingly, the evolving landscape of tumor immunology may benefit from integrating TLS-targeted approaches with existing checkpoint blockade agents, potentially synergizing anti-tumor immunity.

Moreover, the broader implications of TLS extend beyond ESCC into other epithelial malignancies where immune microenvironment cues dictate clinical outcomes. This comprehensive meta-analysis strengthens the paradigm that tumor-infiltrating immune structures serve as essential arbiters of cancer progression and patient survival, advocating for their incorporation as core components in oncological diagnostics and prognostics.

In sum, Yu and colleagues deliver compelling evidence that tertiary lymphoid structures are not mere bystanders but pivotal players shaping the clinical trajectory of esophageal squamous cell carcinoma. Their presence portends improved survival and highlights the nuanced interplay between tumor biology and host immunity. As oncology moves toward precision medicine, TLS stand out as a promising biomarker and therapeutic target, heralding a potential shift in how ESCC is evaluated and treated.

The synthesis of these data offers renewed optimism for ESCC patients and clinicians alike, emphasizing the power of harnessing endogenous immune architectures within tumors. With further validation and clinical translation, TLS could fundamentally alter the prognostic landscape and therapeutic decision-making for this formidable cancer type.

Subject of Research: Prognostic and clinicopathological significance of tertiary lymphoid structures in esophageal squamous cell carcinoma

Article Title: Prognostic and clinicopathological significance of tertiary lymphoid structure in esophageal squamous cell carcinoma: a systematic review and meta-analysis review

Article References:
Yu, Ct., Gao, Y., Liu, Ry. et al. Prognostic and clinicopathological significance of tertiary lymphoid structure in esophageal squamous cell carcinoma: a systematic review and meta-analysis review. BMC Cancer 25, 1544 (2025). https://doi.org/10.1186/s12885-025-14997-x

Image Credits: Scienmag.com

DOI: https://doi.org/10.1186/s12885-025-14997-x